Diana Hausman, a director at Immuneering Corp ($IMRX), made two open market purchases of company shares in the last year, totaling nearly $20,000. Her most recent buy occurred on July 2, 2025. These purchases rank 3,860th among 4,983 insiders in our database by dollar amount, compared to an average of $1.46 million per insider and 3.29 transactions. Hausman reported no open market sales over the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 2, 2025 | Immuneering Corp | $IMRX | HAUSMAN DIANA | Director | P | Class A Common Stock | 2500 | $3.60 | 5,500.0000 | 35,887,252 | 83.33% | 0.01% |
| July 2, 2025 | Immuneering Corp | $IMRX | HAUSMAN DIANA | Director | P | Class A Common Stock | 3000 | $3.62 | 5,500.0000 | 35,887,252 | 120.00% | 0.01% |
| June 13, 2025 | Immuneering Corp | $IMRX | HAUSMAN DIANA | Director | A | Stock Option | 33350 | $0.00 | 33,350.0000 | 35,887,252 | 9999.99% | 0.09% |
| June 12, 2024 | Immuneering Corp | $IMRX | HAUSMAN DIANA | Director | A | Stock Option | 33350 | $0.00 | 33,350.0000 | 0 | 9999.99% | 0.00% |
| May 9, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | HAUSMAN DIANA | Chief Medical Officer | S | Common Stock | 3356 | $12.62 | 373,876.0000 | 0 | 0.89% | 0.00% |
| Feb. 1, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | HAUSMAN DIANA | Chief Medical Officer | A | Common Stock | 337500 | $0.00 | 377,232.0000 | 0 | 849.44% | 0.00% |
| Feb. 1, 2024 | Zentalis Pharmaceuticals, Inc. | $ZNTL | HAUSMAN DIANA | Chief Medical Officer | A | Stock Option (Right to Buy) | 337500 | $0.00 | 337,500.0000 | 0 | 9999.99% | 0.00% |